Management Team

Daojing Wang, Ph.D., Founder and CEO

Dr. Wang founded Newomics Inc. in August 2011 while a Career Scientist and Principal Investigator at Lawrence Berkeley National Laboratory (LBNL), where he had worked since 2002. Dr. Wang launched Newomics in September 2013 to further its technology development and commercialization. Dr. Wang has been continuously serving as a principal investigator for multiple research grants from NIH, DOE, NASA, and CBCRP. He has published extensively in highly respected journals such as Aging Cell, Analytical Chemistry, Cancer Research, Journal of Proteome Research, Molecular and Cellular Proteomics, Proceedings of the National Academy of Sciences, Proteomics, and Trends in Biotechnology etc. Dr. Wang is the co-inventor of multiple issued and pending patents including M3 emitters, MEA chips, and senescence chips, which together lay the foundation for Newomics’ platforms and solutions for precision medicine. Prior to joining LBNL, Dr. Wang had performed research at SurroMed Inc. and the University of California, San Francisco. Dr. Wang obtained his B.S. degree from University of Science and Technology of China (USTC) in 1994, Ph.D. in Chemistry from Princeton University in 1999, and completed his postdoctoral training at the University of California, Berkeley in 2000.

Frank Slovenec, Chief Commercialization Officer

Frank has over 25 years of experience in building and growing high performance customer facing organizations for a range of high-tech solutions and services companies. Frank was the President and COO of GTSI, a publicly traded company, now UNICOM. He tripled the value of the company in his 3-year tenure, earning him Business Man of the Year honors in Federal Integrator space. Frank started his career in sales and has been Vice President of Sales for a number of public and private companies. Included in those companies is Ingram-Micro. Today Ingram-Micro is the largest computer products distributor in the world. He started SalesCEO, a sales training and sales consulting firm in 2000. SalesCEO has worked with technology and medical device companies authoring sales and business development plans and building organizations. Frank earned a Bachelor of Science degree from Cleveland State University, and is an advisor to Sonitus Technologies and Precise Light Surgical.

Steven Bodovitz, Ph.D., Director of Business Development

Dr. Bodovitz has more than 20 years of experience in market planning for developmental therapeutics and for diagnostic and drug discovery technologies. At Aduro Biotech, Inc., first as Associate Director, Strategic Development and then as Associate Director, Market Planning, he identified market opportunities for a broad portfolio of small-molecule, biological and cell-based therapeutics. At BioInsights and BioPerspectives, he identified market opportunities for multiplexed diagnostics as well as biochip, drug screening and omics technologies and was featured as a Proteomics Pioneer in ProteoMonitor and quoted in articles in The Economist, Nature Biotechnology, Science and Genetic Engineering & Biotechnology News. Dr. Bodovitz obtained his Ph.D. in Neuroscience from Northwestern University in 1996.

Pan Mao, Ph.D., Co-Founder and Director of Product Engineering

Dr. Mao co-founded Newomics Inc. with Dr. Wang in August 2011. Dr. Mao is the co-inventor of M3 emitters and MEA chips. Dr. Mao has extensive experience in developing micro/nanofluidic technologies to solve biological problems. He has made significant contributions to the application of micro/nanofluidics for biological sample preparation and development of fully integrated micro/nanofluidic bioanalytical systems to perform high-throughput omics analysis. Dr. Mao has published over 15 papers in well-respected journals such as Analytical Chemistry, Journal of Proteome Research, and Lab-on-a-Chip, and has served as principal investigator and co-investigator at Newomics Inc. for several NIH SBIR projects. Dr. Mao obtained his B.S. degree from USTC in 2002, Ph.D. in Mechanical Engineering from MIT in 2009, and completed his postdoctoral training at LBNL in 2013.